Senti Bio Q3 net loss $28.9M; cash $10.5M; SENTI-202 data expected Q4 2024

Senti Biosciences, Inc.

2024-Q3 EPS reported -$11.41

Net loss $28.9M ($6.31 per share); R&D spend $8.7M (down from $9.1M YoY).
Cash and equivalents $10.5M at Sept 30; subsequent $2.5M CIRM tranche received.
Phase 1 enrollment of SENTI-202 ongoing; initial safety/efficacy data on track by year-end.
CIRM grant total $8.0M; $4.9M received through Nov 2024.
SENTI-301A pilot trial with Celest expects first patient dosing in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.